Bayer Intellectual Property Gmbh

Schering Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer IP Gmbh

Jan-Peter Ingwersen

Michael Dittgen

Sabine Fricke

Thomas Langguth

Dirk Schenk

Stephan Mletzko

Hubert Kaffl

Doris Hubler

Manfred Suesse

Wolfgang Schmidt

Georg Rossling

Hans-Ulrich Moritz

Andreas Briel

Kai Lovis

Jochen Schumacher

Wilhelm Kuhnz

Wilheim Kuhnz

Jochen Schuhmacher

Uwe Budde

The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV-radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.

UV stable transdermal therapeutic plaster with a UV absorbing self-adhesive layer separated from the drug matrix

The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.

UV stable transdermal therapeutic plaster with a UV absorbing adhesive layer separated from the drug matrix

Described are methods for providing prolonged physiologically acceptable steady state serum testosterone levels in a patient deficient in endogenous testosterone levels, methods for male contraception and methods for treating a disease or symptom associated with deficient endogenous levels of testosterone in a man, by intramuscularly administering testosterone esters in a vehicle.

Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels

The present invention relates to pharmaceutical compositions, formulated for injectable administration, which comprises a testosterone ester, in particularly testosterone undecanoate, in a vehicle comprising castor oil and a co-solvent. Upon injecting the compositions according to a particular administration scheme, reliable levels of testosterone in serum in the normal physiological range is achieved for a long period. This allows for the use of the compositions in hormone replacement therapy and male contraception without concomitant monitoring of testosterone levels in serum by a physician.

The invention relates to a multi-stage method for producing gas-filled microcapsules. In one stage of the method, the substance that forms the coat is polymerized. The microcapsules are formed in a physically and/or temporally separate stage, by means of a structuring process. The polymerization is carried out with moderate stirring, while the microcapsules are structured in dispersing conditions.

Multi-stage method for producing gas-filled microcapsules

Growing community of inventors

Berlin, Germany

Jan-Peter Ingwersen